Polyrizon Ltd. PLRZ
11.05 USD +0.10 (+0.91%)
As ofNov 17, 2026, 3:39 PM EST
10.43 Day range 11.01
2.88 52-week range 18.20
- YTD
- +30.15%
- 1 year
- +154.61%
- Market cap
- 26.20M
- EPS (ttm)
- -4.97
- Shares out
- 4.19M
- YTD return
- +30.15%
- 1-year return
- +154.61%
- 50-day average
- 1.17
- Volume
- 13.79K
- Avg volume
- 45.29K
- Open
- 10.71
- Previous close
- 10.95
- Day's range
- 10.43 – 11.01
- 52-week range
- 2.88 – 18.20
No chart data for this range yet.
Key statistics
- 200-day average
- 1.17
- Enterprise value
- 5.46M
- Total cash
- 23.00K
- Total debt
- 151.00K
Fundamental scorecard
6 of 25 checks passed on PLRZ’s reported financials
6of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
PLRZ Revenue — annual 0
PLRZ Net income — annual -3.33M
PLRZ EPS — annual -4.90
About Polyrizon Ltd.
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a containment barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- polyrizon-biotech.com
News
Your note
Sign in to keep a note on PLRZ — it syncs with the Stock Master app.
